Literature DB >> 2911145

Particle size distribution of lipoproteins from human atherosclerotic plaque: a preliminary report.

J H Rapp1, H W Harris, R L Hamilton, W C Krupski, L M Reilly, W K Ehrenfeld, R J Stoney, J Goldstone, J P Kane.   

Abstract

It is commonly believed that low-density lipoproteins (LDLs) carry cholesterol into the artery wall. In addition, some epidemiologic studies have suggested that triglyceride-rich lipoproteins, such as very-low-density lipoproteins (VLDLs), may be much less important than LDLs in atherogenesis. To determine if VLDLs or their metabolic remnants could have a direct role in the formation of atherosclerotic plaque, we examined lipoproteins isolated from endarterectomy specimens. Atherosclerotic plaque was obtained from eight subjects who underwent aortoiliac endarterectomy (4), aortic aneurysm repair (2), or visceral/renal endarterectomy (2). Plaques were washed extensively, minced, and incubated with a buffered saline solution. Lipoproteins were recovered from this solution via a selected-immunoaffinity column by means of a polyclonal antibody to human LDL (apolipoprotein B-100). Particle sizing from electron photomicrographs of negatively stained specimens indicated that 8% of the lipoprotein particles were the size of plasma VLDL (350 to 800 nm). Thirty-six percent were the size of plasma VLDL remnant particles (250 to 350 nm), and 56% were consistent in size with plasma LDL (175 to 250 nm). We conclude that VLDL- and VLDL remnant-sized particles appear to comprise a significant percentage of the lipoproteins found in human atherosclerotic plaque and could have a direct role in the atherosclerotic process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2911145

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  7 in total

1.  Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

Authors:  Julian C van Capelleveen; Sophie J Bernelot Moens; Xiaohong Yang; John J P Kastelein; Nicholas J Wareham; Aeilko H Zwinderman; Erik S G Stroes; Joseph L Witztum; G Kees Hovingh; Kay-Tee Khaw; S Matthijs Boekholdt; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-05-04       Impact factor: 8.311

2.  Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

Authors:  T Ebara; R Ramakrishnan; G Steiner; N S Shachter
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

3.  Regulation of very low density lipoprotein apo B metabolism by dietary fat saturation and chain length in the guinea pig.

Authors:  G Abdel-Fattah; M L Fernandez; D J McNamara
Journal:  Lipids       Date:  1998-01       Impact factor: 1.880

4.  Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions.

Authors:  S Ylä-Herttuala; B A Lipton; M E Rosenfeld; I J Goldberg; D Steinberg; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 5.  The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease.

Authors:  Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-05-26       Impact factor: 10.514

6.  The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletion.

Authors:  Shu-Fen Wung; Medha V Kulkarni; Clive R Pullinger; Mary J Malloy; John P Kane; Bradley E Aouizerat
Journal:  Lipids Health Dis       Date:  2006-07-05       Impact factor: 3.876

7.  Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.

Authors:  Raimund Pechlaner; Sotirios Tsimikas; Xiaoke Yin; Peter Willeit; Ferheen Baig; Peter Santer; Friedrich Oberhollenzer; Georg Egger; Joseph L Witztum; Veronica J Alexander; Johann Willeit; Stefan Kiechl; Manuel Mayr
Journal:  J Am Coll Cardiol       Date:  2017-02-21       Impact factor: 24.094

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.